Xiang Zhou

Title: Xiang Zhou: Innovator in Bispecific Antibody Development

Introduction

Xiang Zhou is a prominent inventor based in Wuhan, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. With a total of 3 patents to his name, Zhou's work is paving the way for innovative treatments in cancer therapy.

Latest Patents

Zhou's latest patents include groundbreaking methods for the preparation and selection of cells for producing bispecific antibodies. One of his notable inventions involves compositions and methods for preparing a cell suitable for producing a bispecific antibody. This process includes incubating a plurality of eukaryotic cells with an agent to allow the cells to arrest at the G1/S phase, followed by transfection with vectors encoding specific antigen-binding units.

Another significant patent is the construction and application of the bispecific antibody HER2xCD3. This invention features a bispecific antibody that comprises a single-chain unit with specific binding capabilities against the CD3 surface antigen of immune cells and a monovalent unit targeting the HER2 surface antigen of tumor cells. The preparation method and pharmaceutical applications of these antibodies are also detailed in this patent.

Career Highlights

Xiang Zhou is currently associated with Wuhan Yzy Biopharma Co., Ltd., where he continues to advance his research in biopharmaceuticals. His innovative approaches have garnered attention in the scientific community, contributing to the development of effective cancer therapies.

Collaborations

Zhou collaborates with talented individuals in his field, including Pengfei Zhou and Jing Zhang, who bring diverse expertise to their projects. Their teamwork enhances the potential for groundbreaking discoveries in biopharmaceutical research.

Conclusion

Xiang Zhou's contributions to the field of bispecific antibodies represent a significant advancement in cancer treatment. His innovative patents and collaborative efforts are set to make a lasting impact on biopharmaceutical development.